Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Onset CE marks heart valve delivery catheter

This article was originally published in Clinica

Executive Summary

Onset Medical has CE marked its SoloPath endovascular access catheter for sale in Europe. The catheter is designed to deliver devices such as heart valves via the femoral and iliac arteries into the larger aortic artery. Up to 20% of patients who require replacement aortic heart valves have severe atherosclerosis in their leg arteries, the Irvine, California firm claims, which may prevent the use of newer percutaneous aortic valves being marketed in Europe by Edwards Lifesciences and Medtronic. In these patients, the valve has to be delivered either through a minimally-invasive incision near the heart or via a totally open-heart surgical procedure. The SoloPath could provide access to these diseased arteries, allowing more patients to be treated with percutaneously implanted aortic heart valves. The SoloPath can also deliver stent grafts for the treatment of aortic aneurysms. Onset expects to launch the SoloPath during the fourth quarter.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT043942

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel